Last reviewed · How we verify

Ten-days oseltamivir + baloxavir marboxil

UMC Utrecht · Phase 3 active Small molecule

Ten-days oseltamivir + baloxavir marboxil is a Neuraminidase inhibitor and cap-dependent endonuclease inhibitor Small molecule drug developed by UMC Utrecht. It is currently in Phase 3 development for Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications.

Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus from infected cells, while baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral replication.

Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus from infected cells, while baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral replication. Used for Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications.

At a glance

Generic nameTen-days oseltamivir + baloxavir marboxil
SponsorUMC Utrecht
Drug classNeuraminidase inhibitor and cap-dependent endonuclease inhibitor
TargetNeuraminidase and cap-dependent endonuclease
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Oseltamivir works by binding to the neuraminidase protein on the surface of influenza virus particles, preventing them from being released from infected cells. Baloxavir marboxil, on the other hand, targets the cap-dependent endonuclease enzyme, which is essential for viral replication. By inhibiting this enzyme, baloxavir marboxil prevents the virus from replicating within host cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ten-days oseltamivir + baloxavir marboxil

What is Ten-days oseltamivir + baloxavir marboxil?

Ten-days oseltamivir + baloxavir marboxil is a Neuraminidase inhibitor and cap-dependent endonuclease inhibitor drug developed by UMC Utrecht, indicated for Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications.

How does Ten-days oseltamivir + baloxavir marboxil work?

Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus from infected cells, while baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral replication.

What is Ten-days oseltamivir + baloxavir marboxil used for?

Ten-days oseltamivir + baloxavir marboxil is indicated for Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications.

Who makes Ten-days oseltamivir + baloxavir marboxil?

Ten-days oseltamivir + baloxavir marboxil is developed by UMC Utrecht (see full UMC Utrecht pipeline at /company/umc-utrecht).

What drug class is Ten-days oseltamivir + baloxavir marboxil in?

Ten-days oseltamivir + baloxavir marboxil belongs to the Neuraminidase inhibitor and cap-dependent endonuclease inhibitor class. See all Neuraminidase inhibitor and cap-dependent endonuclease inhibitor drugs at /class/neuraminidase-inhibitor-and-cap-dependent-endonuclease-inhibitor.

What development phase is Ten-days oseltamivir + baloxavir marboxil in?

Ten-days oseltamivir + baloxavir marboxil is in Phase 3.

What are the side effects of Ten-days oseltamivir + baloxavir marboxil?

Common side effects of Ten-days oseltamivir + baloxavir marboxil include Nausea, Headache, Fatigue, Diarrhea.

What does Ten-days oseltamivir + baloxavir marboxil target?

Ten-days oseltamivir + baloxavir marboxil targets Neuraminidase and cap-dependent endonuclease and is a Neuraminidase inhibitor and cap-dependent endonuclease inhibitor.

Related